Dare-LARC1
Microchip Implant
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Subdermal
-
Intended Duration:
- Long-Acting
- Development Stage: Pre-Clinical
- Developer(s)/researcher(s): Dare BioScience Inc.
Details
- API: Levonorgestrel
- Target: Progesterone Receptor
-
Mechanism of Action:
- Ovulation Inhibition
- Cervical Mucus Changes
- Endometrial Changes
- Inactive Materials: Not Yet Determined
- Regimen: Not Yet Determined
- MPT: Not Potential MPT
- Promising Attributes: Developers indicate their intent to develop a low-cost, user controlled LARC, a product profile not currently available in the contraceptive market.
Product Status
Active Pre-Clinical Research
History
2019: Daré Bioscience acquires Microchip Biotech for its wireless, user-controlled drug delivery platform
2021: SEC filings indicate that Daré Bioscience will receive grant funding to support the development of an "investigational user-controlled long-active reversible contraceptive"
2023: Daré announces that the development platform has advanced sufficiently to receive the second installment of their grant funding
2024: Daré announces that the company has finalized their proof-of-concept device, which will enable clinical research in the future. The device can be be turned on (releasing hormones) and off by the user to align with their fertility intentions and needs.
2025: Daré announces receipt of $4M non-dilutive grant installment, bringing total received funding for DARE-LARC1 to $41.8M for pre-clinical evaluation and IND-enabling research